JP2025515706A5 - - Google Patents

Info

Publication number
JP2025515706A5
JP2025515706A5 JP2024566219A JP2024566219A JP2025515706A5 JP 2025515706 A5 JP2025515706 A5 JP 2025515706A5 JP 2024566219 A JP2024566219 A JP 2024566219A JP 2024566219 A JP2024566219 A JP 2024566219A JP 2025515706 A5 JP2025515706 A5 JP 2025515706A5
Authority
JP
Japan
Prior art keywords
approximately
fluoro
amount
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024566219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515706A (ja
JP7767651B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/021637 external-priority patent/WO2023220109A1/en
Publication of JP2025515706A publication Critical patent/JP2025515706A/ja
Publication of JP2025515706A5 publication Critical patent/JP2025515706A5/ja
Priority to JP2025182180A priority Critical patent/JP2026021422A/ja
Application granted granted Critical
Publication of JP7767651B2 publication Critical patent/JP7767651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024566219A 2022-05-11 2023-05-10 Ｇｌｐ１医薬組成物 Active JP7767651B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182180A JP2026021422A (ja) 2022-05-11 2025-10-29 Ｇｌｐ１医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263340591P 2022-05-11 2022-05-11
US63/340,591 2022-05-11
PCT/US2023/021637 WO2023220109A1 (en) 2022-05-11 2023-05-10 Glp1 pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182180A Division JP2026021422A (ja) 2022-05-11 2025-10-29 Ｇｌｐ１医薬組成物

Publications (3)

Publication Number Publication Date
JP2025515706A JP2025515706A (ja) 2025-05-20
JP2025515706A5 true JP2025515706A5 (https=) 2025-06-18
JP7767651B2 JP7767651B2 (ja) 2025-11-11

Family

ID=86732348

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024566219A Active JP7767651B2 (ja) 2022-05-11 2023-05-10 Ｇｌｐ１医薬組成物
JP2025182180A Pending JP2026021422A (ja) 2022-05-11 2025-10-29 Ｇｌｐ１医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182180A Pending JP2026021422A (ja) 2022-05-11 2025-10-29 Ｇｌｐ１医薬組成物

Country Status (17)

Country Link
US (1) US20250302809A1 (https=)
EP (1) EP4522129A1 (https=)
JP (2) JP7767651B2 (https=)
KR (1) KR20250002778A (https=)
CN (1) CN119173255A (https=)
AR (1) AR129296A1 (https=)
AU (1) AU2023269995A1 (https=)
CA (1) CA3253043A1 (https=)
CL (1) CL2024003392A1 (https=)
CO (1) CO2024015285A2 (https=)
DO (1) DOP2024000232A (https=)
IL (1) IL316629A (https=)
JO (1) JOP20240245A1 (https=)
MX (1) MX2024013839A (https=)
PE (2) PE20260136A1 (https=)
TW (2) TW202508581A (https=)
WO (1) WO2023220109A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4522131A1 (en) * 2022-05-11 2025-03-19 Eli Lilly and Company Glp1 tablet compositions
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202540124A (zh) * 2023-11-21 2025-10-16 大陸商江蘇恆瑞醫藥股份有限公司 雜環類化合物、其製備方法及其在醫藥上的應用
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434641A1 (en) * 2001-01-18 2002-08-22 Pharmacia And Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2008030524A2 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7461104B2 (ja) 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CA3191084A1 (en) 2020-09-09 2022-03-17 Gerald Burke Formulations of a somatostatin modulator
EP4522131A1 (en) 2022-05-11 2025-03-19 Eli Lilly and Company Glp1 tablet compositions

Similar Documents

Publication Publication Date Title
JP2025515706A5 (https=)
IL316629A (en) GLP1 drug compounds
RU2574018C2 (ru) Легко дозируемый твердый препарат
JPH0399016A (ja) 二重被覆顆粒
CN107049979B (zh) 易服用性固体制剂
KR102072618B1 (ko) 서방성 토피라메이트 캡슐
JPWO2008010524A1 (ja) 水易溶性薬物含有球状素顆粒の製造方法
IL316478A (en) GLP1 tablet preparations
CN102091051A (zh) 一种别嘌醇双释放制剂及其制备方法
KR20230057388A (ko) Sglt-2 억제제와 안지오텐신 수용체 길항제의 조성물 및 이의 용도
TW201414508A (zh) 含５－氯－ｎ－（｛（５ｓ）－２－側氧－３－［４－（３－側氧－４－嗎啉基）苯基］－１，３－□唑啶－５－基｝甲基）－２－噻吩甲醯胺之醫藥投遞型式
US20180015080A1 (en) Compositions and methods for treatment in parkinson's disease patients
JP2018118966A (ja) ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP2018118966A5 (https=)
CN108201529B (zh) 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法
JPH0692849A (ja) フラン誘導体を含有する医薬組成物
US20140271839A1 (en) Extended-release topiramate capsules
TWI574705B (zh) Capsules
WO2015008825A1 (ja) 口腔内崩壊錠
JP4902928B2 (ja) 製剤の安定化方法
EP3973030A1 (en) Compositions and methods for the treatment and mitigation of alcohol-induced skin flushing
JP2017119714A (ja) メドキソミル基を有するプロドラッグを含有するフィルムコーティング製剤
JPS60163823A (ja) 経口投与製剤
JP2025535941A5 (https=)
JP2023083990A (ja) シタグリプチンリン酸塩無水物経口製剤の安定化方法および用途